ERBB2 and triple-negative breast carcinoma: They found that the expression of HER2 mRNA in CTCs did not reflect the clinical diagnosis of HER2 status, and continuous evolutionary changes of HER2 mRNA were observed also in different patients, including those with triple-negative breast cancer (TNBC).